ARTÍCULOS-tratamiento

NOTA: En esta sección se recogen únicamente artículos elaborados por autores españoles o pertenecientes a instituciones españolas.

.

.General

Andrade-Campos M, et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies? Blood Cells Mol Dis. 2020 Jul 14;85:102478 [doi

Berenguer J, et al. Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020 Aug 4;S1198-743X(20)30431-6 [doi

Borobia AM, et al. A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. J Clin Med. 2020;9(6):1733 [doi

Bosch-Barrera J, et al. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. J Clin Med. 2020;9(6):1770 [doi

Corral Gudino L. El tratamiento de la pandemia por COVID 19. Ante la expectativa de evitar una oportunidad perdida [texto completo]. Rev Clin Esp. 2020 Apr 15 [doi]  

De la Rica R, et al. Low Albumin Levels Are Associated with Poorer Outcomes in a Case Series of COVID-19 Patients in Spain: A Retrospective Cohort Study. Microorganisms. 2020 Jul 24;8(8):E1106 [doi]

De Medrano VAL, et al. Tomar o no tomar «decisiones en caliente» respecto al tratamiento de la infección por SARS-CoV-2 [texto completo]. Rev Clin Esp. 2020 Apr 15 [doi]  

Huttner B, et al. COVID-19: don’t neglect antimicrobial stewardship principles! [texto completo]. Clin Microbiol Infect. 2020 Apr 29;S1198-743X(20)30232-9 [doi]

López Reboiro ML, et al. COVID-19 y Argumentum ad ignorantiam o «no todo vale»  [texto completo]. Rev Clin Esp. 2020 May 4;10.1016/j.rce.2020.04.013 [doi]

Marta-Enguita J, et al. Factores de riesgo y predictores de gravedad en pacientes hospitalizados por COVID-19: análisis de 52 casos. Med Clin (Barc). 2020 Jun 25;S0025-7753(20)30401-2 [doi

Martos Pérez F, et al. Comorbilidad y factores pronósticos al ingreso en una cohorte COVID-19 de un hospital general. Rev Clin Esp. 2020 Jun 26;S0014-2565(20)30179-X [doi

Parzych E, et al. Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective. J Allergy Clin Immunol. 2020 Jul 2;S0091-6749(20)30951-9 [doi

Reina J. El SARS-CoV-2, una nueva zoonosis pandémica que amenaza al mundoVacunas. 2020;21(1):17-22 [doi

Rivera-Izquierdo M, et al. Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad. Med Clin (Barc). 2020 Jul 9;S0025-7753(20)30448-6 [doi

Ye Z, et al. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. CMAJ. 2020;192(20):E536-E545 [doi

.

Alergología

Barroso B, et al. Presenting prevalence, characteristics and outcome of asthmatic patients with T2 diseases in hospitalized subjects with COVID-19 in Madrid, Spain. J Investig Allergol Clin Immunol. 2020;0 [doi]

.

Anestesiología

Tusman G, et al. COVID-19: cómo transformar un ventilador de no invasiva en un ventilador de críticos. Rev Esp Anestesiol Reanim. 2020;S0034-9356(20)30117-1 [doi

Cinesi Gómez C, et al. Recomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infección por SARS-CoV-2. Rev Esp Anestesiol Reanim. 2020;67(5):261-270 [doi

Hernández A, et al. Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19 [texto completo]. Rev Esp Anestesiol Reanim. 2020 Apr 14:S0034-9356(20)30075-X [doi]

.

Aparato digestivo

Colmenero J, et al. Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2020 Aug 1;S0168-8278(20)30521-3 [doi

.

Cardiología

Jiménez Hernández S, et al. Características clínicas, factores de riesgo y resultados finales de pacientes con COVID-19 diagnosticados de tromboembolia de pulmón en urgencias. Emergencias. 2020;32(4):253-257

Hamadeh A, et al. Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. Am J Cardiol. 2020 Jul 3;S0002-9149(20)30641-X [doi

Soria Arcos F, et al. Controversias sobre el tratamiento con IECA/ARA-II y Covid-19 [texto completo]. Rev Esp Cardiol. 2020 Apr 10;10.1016/j.recesp.2020.03.014 [doi

Eiras S, et al. COVID-19 and treatment guided by biochemical and molecular diagnostic tests to reduce myocardial damage and cardiotoxicity [texto completo]. Rev Esp Cardiol (Engl Ed). 2020;73(8):691-693 [doi]

Torres González N, et al. Electrocardiographic/QT interval monitoring with a portable device in hospitalized patients with COVID-19: a protocol proposal [published online ahead of print, 2020 Jun 25]. Rev Esp Cardiol (Engl Ed). 2020 Jun 25;S1885-5857(20)30278-4 [doi]

Vivas D, et al. Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología [texto completo]. Rev Esp Cardiol. 2020 Apr 22 [doi

Vivas D, et al. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed). 2020 Jun 19;S1885-5857(20)30272-3 [doi

Moreno G, et al. Revisión sistemática sobre la utilidad pronóstica del dímero-D, coagulación intravascular diseminada y tratamiento anticoagulante en pacientes graves con COVID-19. Med Intensiva. 2020 Jun 17;S0210-5691(20)30187-X [doi

Lorca R, Triviño RL, Morís C. Tratamiento de pacientes de cardio-onco-hematología durante la pandemia actual por COVID-19 [texto completo]. Rev Esp Cardiol. 2020 May 11;10.1016/j.recesp.2020.05.002 [doi]

.

Cirugía

Montero Feijoo A, et al. Recomendaciones prácticas para el manejo perioperatorio del paciente con sospecha o infección grave por coronavirus SARS-CoV-2 [texto completo]. Rev Esp Anestesiol Reanim. 2020;S0034-9356(20)30053-0 [doi]

.

Cuidados intensivos

Ferrando C, et al. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive Care Med. 2020 Jul 29;1-12 [doi

Belenguer-Muncharaz A, et al. Fracaso de la ventilación no invasiva tras empleo de oxigenoterapia de alto flujo en pacientes con neumonía por SARS-CoV-2. Med Intensiva. 2020 Jul 9;S0210-5691(20)30220-5 [doi

González Cortés R, et al. A multicenter national survey of children with SARS-CoV-2 infection admitted to Spanish Pediatric Intensive Care Units. Intensive Care Med. 2020;1-3 [doi

González-Castro A, et al. Ventilación mecánica no invasiva y oxigenoterapia de alto flujo en la pandemia COVID-19: El valor de un empate. Med Intensiva. 2020;S0210-5691(20)30156-X [doi

Tornero C, et al. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial”. Trials. 2020;21(1):576 [doi

.

Dermatología

Andina D, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol. 2020;37(3):406-411 [doi

Pastor Nieto MA, et al. Prior treatment with immunosuppressants among COVID-19 inpatients at one hospital in Spain. J Eur Acad Dermatol Venereol. 2020 Jun 28;10.1111/jdv.16798 [doi

.

Endocrinología

Frías Vargas M, et al. Tratamiento hipolipemiante en la era COVID-19. Semergen. 2020 Jul 1;S1138-3593(20)30206-9 [doi

.

Geriatría

Callejas Rubio JL, et al. Tratamiento y evolución del síndrome de tormenta de citoquinas asociados a infección por SARS-CoV-2 en pacientes octogenarios. Rev Esp Geriatr Gerontol. 2020;S0211-139X(20)30063-9 [doi

Mostaza JM, et al. Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population. Arch Gerontol Geriatr. 2020 Jul 27;91:104204 [doi

.

Hematología

van Doesum J, et al. Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands. Leukemia. 2020 Jul 8;1-3 [doi

.

Nefrología

Florit EA, et al. ¿Es la hiporrespuesta inmune de la uremia un factor de protección contra la neumonía grave por COVID-19? Nefrologia. 2020 May 23;S0211-6995(20)30064-3 [doi]

Lamas Barreiro JM, et al. Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica. Nefrologia. 2020;40(3):213-216 [doi]  

.

Neumología

Del Campo F, et al. Estudio de la adherencia al tratamiento con presión continua positiva en la vía aérea en pacientes con síndrome de apnea obstructiva del sueño en el confinamiento impuesto durante la pandemia de COVID-19. Arch Bronconeumol. 2020 Jul 16;S0300-2896(20)30222-2 [doi]

Díaz Lobato S, et al. ¿Podemos usar terapias respiratorias no invasivas en la pandemia COVID-19? Med Clin (Barc). 2020;155(4):183 [doi

Farré R, et al. Ventiladores mecánicos de emergencia para la COVID-19. Arch Bronconeumol. 2020;56 Suppl 2:7-8 [doi

Gea J, et al. Posibles limitaciones en la utilización de la presión arterial de oxígeno en procesos respiratorios por SARS-CoV-2. Arch Bronconeumol. 2020;56 Suppl 2:9-10 [doi

González-Gerez JJ, et al. Therapeutic pulmonary telerehabilitation protocol for patients affected by COVID-19, confined to their homes: study protocol for a randomized controlled trial. Trials. 2020;21(1):588 [doi

Martínez-Pizarro S. Rehabilitación respiratoria en pacientes con COVID-19 [texto completo]. Rehabilitacion (Madr). 2020 May 14;10.1016/j.rh.2020.04.002 [doi]

Pérez Pallarés J, et al. Recomendaciones de consenso SEPAR-AEER sobre la utilidad de la ecografía torácica en el manejo del paciente con sospecha o infección confirmada con COVID-19. Arch Bronconeumol. 2020;56 Suppl 2:27-30 [doi

Rodríguez-Sevilla J, et al. Pulmonary Embolism in Patients With Covid-19 Pneumonia: The Utility of D-dimer. Arch Bronconeumol. 2020 Jul 15;S0300-2896(20)30216-7 [doi

Segura Alba O, et al. Dispositivo de oxigenación con reservorio y PEEP (DORPEEP) en pacientes con dificultad respiratoria aguda por COVID-19 [texto completo]. Med Clin (Barc). 2020;S0025-7753(20)30260-8 [doi]

.

Obstetricia y ginecología

González R, et al. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. Trials. 2020 Jul 2;21(1):607 [doi

Martínez-Perez O, et al. Association Between Mode of Delivery Among Pregnant Women With COVID-19 and Maternal and Neonatal Outcomes in Spain. JAMA. 2020;e2010125 [doi]  [published correction appears in JAMA. 2020 Jul 21;324(3):305]

Gracia-Perez-Bonfils A, et al. Fetal heart rate changes on the cardiotocograph trace secondary to maternal COVID-19 infection. Eur J Obstet Gynecol Reprod Biol. 2020;252:286-293 [doi

Ramírez I, et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Maturitas. 2020;137:57‐62 [doi]

.

Oncología

Kuderer NM, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918 [doi

Faura A, et al. Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. Pediatr Blood Cancer. 2020 Jul 16;e28557 [doi

Lara Álvarez MÁ, et al. Mortalidad por covid-19 en pacientes con cáncer en un hospital de Madrid durante las primeras 3 semanas de epidemia. Med Clin (Barc). 2020;S0025-7753(20)30281-5 [doi

Pinato DJ, et al. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. Cancers (Basel). 2020 Jul 8;12(7):E1841 [doi

Flamarique S, et al. Reirradiación con radioterapia estereotáxica corporal (SBRT) en recidiva irresecable de cáncer de cabeza y cuello: a propósito de un caso. An Sist Sanit Navar. 2019;42(3):339-343 [doi]

.

Pediatría

Gimeno-Costa R, et al. Insuficiencia respiratoria COVID-19: soporte con ECMO para niños y adultos jóvenes. An Pediatr (Barc). 2020 Jun 11;S1695-4033(20)30188-0 [doi]

Velasco Puyó P, et al. Tocilizumab en niño con leucemia linfoblástica aguda y síndrome de liberación de citoquinas asociado a COVID-19. An Pediatr (Barc). 2020;93(2):132-133 [doi]  

.

Reumatología

Garcia-Guillén A, et al. COVID-19: La visión del residente de reumatología. Reumatol Clin. 2020;S1699-258X(20)30134-0 [doi

Fernandez-Gutierrez B. COVID-19 con afectación pulmonar. Una enfermedad autoinmune de causa conocida. Reumatol Clin. 2020;16(4):253-254 [doi

Santos CS, et al. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol. 2020 Jul 27;1-8 [doi

Freites Nuñez DD, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Aug 7;annrheumdis-2020-217984 [doi

.

Trasplantes

Cravedi P, et al. COVID-19 and Kidney Transplantation: Results from the TANGO International Transplant Consortium. Am J Transplant. 2020 Jul 10;10.1111/ajt.16185 [doi]

González J, et al. Early experience with COVID-19 in kidney transplantation recipients: update and review. Int Braz J Urol. 2020;46(suppl.1):145-155 [doi

Forns X, et al. Inmunosupresión en el trasplante hepático en la era covid-19. Gastroenterol Hepatol. 2020 Jun 12;S0210-5705(20)30215-6 [doi]

Sánchez Cadena AD, et al. Inmunoglobulinas por vía intravenosa: una alternativa terapéutica a tener en cuenta en el paciente trasplantado renal con COVID-19. Nefrologia. 2020;S0211-6995(20)30065-5 [doi

.

Tratamientos. Anakinra

Figuero-Pérez L, et al. Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab. Reumatol Clin. 2020;S1699-258X(20)30142-X [doi

Muñoz-Jiménez A, et al. Propuesta de uso de anakinra en el distrés respiratorio agudo secundario a COVID-19 [texto completo]. Reumatol Clin. 2020 Apr 27;S1699-258X(20)30086-3 [doi]

.

Tratamientos. Anticoagulantes

Ayerbe L, et al. The association between treatment with heparin and survival in patients with Covid-19 [texto completo]. J Thromb Thrombolysis. 2020 May 31;1‐4 [doi]

.

Tratamientos. Antimaláricos

Cuadrado-Lavín A, et al. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 3;21(1):472 [doi]

Santillán García A, et al. Evidencia viva como respuesta a las controversias en el uso de antimaláricos en COVID-19. Rev Esp Cardiol. 2020;73(8):693-694 [doi]

Cairoli E, et al. Hidroxicloroquina en el tratamiento del COVID-19: como utilizarla a la espera de evidencia científica concluyente. Med Clin (Barc). 2020 May 16;10.1016/j.medcli.2020.05.006 [doi]

González R, et al. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. Trials. 2020 Jul 2;21(1):607 [doi

Mitjà O, et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis. 2020 Jul 16;ciaa1009 [doi

Rodriguez-Valero N, et al. Malaria prophylaxis approach during COVID-19 pandemic [texto completo]. Travel Med Infect Dis. 2020 Apr 29;101716 [doi]

Grau-Pujol B, et al. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial. Trials. 2020;21(1):688 [doi]

Guzman-Prado Y. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19. Am J Cardiol. 2020 Jun 9;S0002-9149(20)30559-2 [doi

Mayayo-Vicente S, et al. Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19. Semergen. 2020 Jul 11;S1138-3593(20)30224-0 [doi]

Lasheras I, et al. Uso de antipalúdicos en el tratamiento del COVID-19: ¿una ventana de oportunidad? [texto completo]. Med Clin (Barc). 2020 Apr 22;S0025-7753(20)30244-X [doi]

.

Tratamientos. Antivirales

Brandáriz Núñez D, et al. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir. Med Clin (Barc). 2020 jul 9;S0025-7753(20)30450-4 [doi]

Reina J. Remdesivir, la esperanza antiviral frente al SARS-CoV-2 [texto completo]. Rev Esp Quimioter. 2020 Jun;33(3):176-179 [doi]

.

Tratamientos. Cannabis

Pascual Pastor F, et al. Cannabis terapéutico y COVID-19: entre el oportunismo y la infoxicación. Adicciones. 2020 Jul 1;32(3):167-172 [doi

.

Tratamientos. Células madre

Soler Rich R, et al. Abordaje terapéutico del SARS-CoV-2 (COVID-19) mediante células mesenquimales de médula ósea alogénica expandidas. Conceptos a propósito de un primer caso en España. Med Clin (Barc). 2020 Jul 3;S0025-7753(20)30407-3 [doi

.

Tratamientos. Ciclosporina

Sanchez-Pernaute O, et al. Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia [texto completo]. Reumatol Clin. 2020 Apr 16;S1699-258X(20)30044-9 [doi]

.

Tratamiento. Corticosteroides

Johnson RM, et al. Dexamethasone in the management of covid -19. BMJ. 2020 Jul 3;370:m2648 [doi

Fernández Cruz A, et al. Impact of glucocorticoid treatment in sars-cov-2 infection mortality: a retrospective controlled cohort study. Antimicrob Agents Chemother. 2020;AAC.01168-20 [doi

Sanz Herrero F, et al. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study. J Intern Med. 2020 Jun 30;10.1111/joim.13145 [doi]

Saiz-Rodríguez M, et al. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial. Trials. 2020 Jul 9;21(1):632 [doi

.

Tratamientos. Duiréticos

Brennecke A, et al. Is Inhaled Furosemide a Potential Therapeutic for COVID-19? Am J Med Sci. 2020 Jun 1;S0002-9629(20)30238-X [doi

.

Tratamientos. Estatinas

Lima Martínez MM, et al. Estatinas en COVID-19: ¿existe algún fundamento? Clin Investig Arterioscler. 2020 Jul 2;S0214-9168(20)30063-2 [doi

.

Tratamientos. Inhibidores del sistema renina-angiotensina-aldosterona

Soria Arcos F, et al. Controversias sobre el tratamiento con IECA/ARA-II y COVID-19. Rev Esp Cardiol (Engl Ed). 2020;73(6):516 [doi]

López-Otero D, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry. Rev Esp Cardiol (Engl Ed). 2020 Jun 5;S1885-5857(20)30224-3 [doi]

Usman MS, et al. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 [published online ahead of print, 2020 Jun 2]. Am J Cardiol. 2020 Jun 2;S0002-9149(20)30548-8 [doi

Amat-Santos IJ, et al. Ramipril in High Risk Patients with COVID-19 [texto completo]. J Am Coll Cardiol. 2020 May 22;S0735-1097(20)35395-X [doi]

Quinn KL, et al. Renin-angiotensin-aldosterone system inhibitors and COVID-19. CMAJ. 2020;192(20):E553-E554 [doi

Golpe R, et al. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. Med Clin (Barc). 2020 Jun 25;S0025-7753(20)30402-4 [doi

Lamas-Barreiro JM, et al. Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica [texto completo]. Nefrologia. 2020 Apr 30;S0211-6995(20)30044-8 [doi]

De Abajo FJ, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study [texto completo]. Lancet. 2020 May 30;395(10238):1705-1714 [doi]

.

Tratamientos. Ivermectina

López Reboiro ML, et al. Réplica: Ivermectina en COVID-19. ¿Argumentum ad ignorantiam? Rev Clin Esp. 2020 Jul 4;S0014-2565(20)30197-1 [doi

Chaccour C, et al. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials. 2020;21(1):498 [doi

.

Tratamientos. Melatonina

Acuña-Castroviejo D, et al. Clinical trial to test the efficacy of melatonin in COVID-19. J Pineal Res. 2020 Aug 8;e12683 [doi

Rodríguez-Rubio M, et al. A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Aug 5;21(1):699 [doi

García IG, et al. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 3;21(1):466 [doi]

.

Tratamientos. Plasma de convalenciente

Zeng QL, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. J Infect Dis. 2020;222(1):38-43 [doi

.

Tratamientos. Reacciones adversas

Herrera-Lasso Regás V, et al. Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2. Med Clin (Barc). 2020 Jul 9;S0025-7753(20)30442-5 [doi

Novo de Matos J, et al. Síndrome de DRESS simulando enfermedad por coronavirus 2019-NcoV. Semergen. 2020;S1138-3593(20)30173-8 [doi]

.

Tratamientos. Tocilizumab

Moreno-Pérez O, et al. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study [published online ahead of print, 2020 Jul 16]. J Autoimmun. 2020 Jul 16;102523 [doi

Sanz Herrero F, et al. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study. J Intern Med. 2020 Jun 30;10.1111/joim.13145 [doi]

Velasco Puyó P, et al. Tocilizumab en niño con leucemia linfoblástica aguda y síndrome de liberación de citoquinas asociado a COVID-19. An Pediatr (Barc). 2020 Jun 9;S1695-4033(20)30180-6 [doi

Jiménez-Brítez G, et al. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience. Med Clin (Barc). 2020 Jul 9;S0025-7753(20)30441-3 [doi

.

Tratamientos. Vitamina D

Quesada Gómez JM, et al. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166 [texto completo]. J Steroid Biochem Mol Biol. 2020 Jun 11;105719 [doi]

.

Urgencias

Martín-Sánchez FJ, et al. Clinical presentation and outcome across age categories among patients with COVID-19 admitted to a Spanish Emergency Department [published online ahead of print, 2020 Jul 16]. Eur Geriatr Med. 2020 Jul 16;1-13 [doi]

Gil-Rodrigo A, et al. Evaluación de las características clínicas y evolución de pacientes con COVID-19 a partir de una serie de 1000 pacientes atendidos en servicios de urgencias españoles. Emergencias. 2020;32(4):233-241